Table 1.
Study patient demographics.
| Characteristic | Patients |
|---|---|
| Age (n = 19) | |
| Mean ± SD | 68.6 ± 11.2 |
| Median (IQR) | 71 (64–76) |
| Sex—no. (%) | |
| Male | 9 (47.4) |
| Female | 10 (52.6) |
| Baseline ECOG—no. (%) | |
| 0 | 8 (42.1) |
| 1 | 11 (57.9) |
| T stage—no. (%) | |
| T4 | 19 (100) |
| N stage—no. (%) | |
| Nx | 2 (10.5) |
| N0 | 14 (73.7) |
| N1 | 3 (15.8) |
| M stage—no. (%) | |
| M0 | 19 (100) |
| SBRT dosage—no. (%) | |
| 50 Gy | 12 (63.2) |
| 55 Gy | 7 (36.8) |
| Chemotherapy—no. (%) * | |
| Gemcitabine and abraxane | 11 (57.9) |
| Folfirinox | 13 (68.4) |
| Tumor location—no. (%) | |
| Head | 8 (42.1) |
| Body | 9 (47.4) |
| Tail | 2 (10.5) |
| Baseline CA 19-9 (n = 18) | |
| Mean ± SD | 178.2 ± 513.9 |
| Median (IQR) | 29.6 (8–60.4) |
* Some patients received multiple types of chemotherapy.